Sanofi continued its growth trajectory. Strong increase in Q1 2021 business EPS(1) at CER
The Pharma Data
APRIL 27, 2021
Progress on implementation of the Corporate Social Responsibility strategy. Strong increase in Q1 2021 business EPS ( 1) at CER. Q1 2021 sales increase of 2.4% at CER driven by growth drivers Dupixent ® and Vaccines. Specialty Care sales grew 15.3%, due to strong Dupixent ® performance (+45.6% to €1,047 million) and oncology launches.
52 
Let's personalize your content